Docetaxel: response in patients who have received at least two prior chemotherapy regimes for metastatic breast cancer

By Archer C.D.   Lowdell C.   Sinnett H.D.   English J.   Khan S.   Coombes R.C.  

European Journal of Cancer, Vol. 34, Iss. 6, 1998-05 ,pp. : 816-819

Elsevier

Access to resources Recommend Favorite

A phase I multicenter study of antroquinonol in patients with metastatic non-small-cell lung cancer who have received at least two prior systemic treatment regimens, including one platinum-based chemotherapy regimen

By        

Molecular and Clinical Oncology, Vol. 3, Iss. 6, 2015-01 ,pp. : 1375-1380

Science Publishers

Access to resources Recommend Favorite

Phase II study evaluating lapatinib in combination with nab -paclitaxel in HER2-overexpressing metastatic breast cancer patients who have received no more than one prior chemotherapeutic regimen

By Yardley Denise  

Breast Cancer Research and Treatment, Vol. 137, Iss. 2, 2013-01 ,pp. : 457-464

Springer Publishing Company

Access to resources Recommend Favorite

Prospective assessment of chemotherapy-induced peripheral neuropathy due to weekly paclitaxel in patients with advanced or metastatic breast cancer (CSP-HOR 02 study)

By Kuroi Katsumasa   Shimozuma Kojiro   Ohashi Yasuo   Hisamatsu Kazufumi   Masuda Norikazu   Takeuchi Ayano   Aranishi Toshihiko   Morita Satoshi   Ohsumi Shozo   Hausheer Frederick  

Supportive Care in Cancer, Vol. 17, Iss. 8, 2009-08 ,pp. : 1071-1080

Springer Publishing Company

Access to resources Recommend Favorite

Vinorelbine is well tolerated and active in the treatment of elderly patients with advanced non-small cell lung cancer. A two-stage phase II study

By Gridelli C.   Perrone F.   Gallo C.   De Marinis F.   Ianniello G.   Cigolari S.   Cariello S.   Di Costanzo F.   D'Aprile M.   Rossi A.   Migliorino R.   Bartolucci R.   Bianco A.R.   Pergola M.   Monfardini S.  

European Journal of Cancer, Vol. 33, Iss. 3, 1997-03 ,pp. : 392-397

Elsevier

Access to resources Recommend Favorite